FOSUN HEALTH Logo

Multiple Myeloma Treatment

catalogue

Multiple Myeloma Treatment

Multiple Myeloma Treatment

Multiple myeloma is treated continuously rather than for a fixed course, and the plan is built from a small number of drug classes used in combination. Two questions decide the shape of first-line treatment: whether the patient is a candidate for high-dose treatment with an autologous stem cell transplant, and whether any organ — particularly the kidney — limits what can be given safely. Age on its own does not answer either question. The disease is then followed by measuring the protein it produces, and the depth of each response decides what comes next.

What decides the first-line plan

Two assessments are made before any treatment is chosen, and they matter more than the stage:

  • Is a transplant realistic? This depends on fitness rather than on age — kidney function, heart function, other illnesses and the patient's own performance status. A fit patient in their seventies may be a candidate, and a frailer patient in their fifties may not.
  • What does the kidney allow? Renal impairment is common at diagnosis and it changes the drugs and their doses. Some drugs can be given at full dose and are actively preferred when the kidney is affected; others need dose reduction; anti-inflammatory painkillers and some contrast agents are avoided altogether.
  • What do the chromosomes say? Disease carrying particular high-risk findings is a reason to favour a more intensive initial approach and to monitor the response more closely rather than less.
  • Are there symptoms that need treating immediately? A raised calcium level, a spinal lesion threatening the cord, a fracture or an infection are dealt with at the same time as the myeloma, not after it.

Induction: the first combination

Initial treatment is given as a combination, because the classes act on the plasma cell in different ways and the combination is more effective than any of them alone:

  • A proteasome inhibitor — the anchor of most regimens. It interferes with the machinery that disposes of damaged proteins, which the plasma cell depends on heavily because it produces so much antibody.
  • An immunomodulatory drug — acts both on the myeloma cell and on the marrow environment that supports it. It is one of the reasons long-term continuous treatment is possible, and it requires attention to clotting risk and to the blood count.
  • A steroid — used at a dose that is part of the regimen rather than as a general measure, and usually tapered over the treatment period rather than given indefinitely.
  • An anti-CD38 antibody — added to the combination in the first line for most patients, since it improves the depth of response when added to the standard three.
  • Four to six cycles is the usual length before the response is assessed, and the assessment is by the protein level and the light chain ratio rather than by how the patient feels.
  • Dose adjustment is expected, not a setback — peripheral neuropathy from one drug class and low blood counts from another are managed by adjusting the dose or the schedule, and completing a regimen at a reduced dose is preferable to abandoning it.

High-dose treatment with autologous transplant

For patients who are fit enough and whose disease has responded, the standard plan includes high-dose treatment followed by return of the patient's own stem cells. It is worth being precise about what this is and is not:

  • The cells are the patient's own, collected from the blood by apheresis before treatment and frozen. This is an autologous transplant, and it does not carry the risks of graft-versus-host disease that a donor transplant does.
  • The purpose is to allow a higher dose of treatment than the marrow could otherwise survive, which deepens the response and lengthens the period of control. It is not a permanent removal of the disease.
  • The sequence — stem cells are collected after induction, high-dose treatment is given, the cells are returned, and the blood counts recover over the following weeks. Patients are usually in hospital for several weeks.
  • Not everyone needs or can have it. It is usually deferred when the response to induction is inadequate, when the kidney or heart will not tolerate it, or when age and frailty make the recovery period unsafe.
  • Donor transplant is used far less often in myeloma than in leukaemia, and it is generally reserved for selected high-risk or relapsed cases because the risks are substantially greater.

Maintenance and continuous treatment

Myeloma is not treated to a fixed endpoint and then stopped. After the initial phase, treatment continues at a lower intensity, and the reason is that the response to treatment is measured rather than assumed:

  • After a transplant, a single oral immunomodulatory drug taken at a reduced dose is the usual maintenance, continued while it is working and tolerated.
  • For patients who did not have a transplant, the initial combination is continued, or a lower-intensity combination is given until the disease progresses, rather than stopped after a set number of cycles.
  • Monitoring is the other half of maintenance — the protein and the light chain ratio are measured at defined intervals, and the result decides whether the current treatment continues.
  • Treatment is not indefinite by rule. Because a deep and sustained response sometimes allows the intensity to be reduced or the treatment to be paused, the plan should state what would trigger a change in either direction.
  • Long-term treatment has side effects that need managing — an increased risk of infection and of blood clots, low blood counts, and second cancers occurring rarely, all of which are reasons for review rather than reasons to stop without discussion.

When the disease returns

Most patients eventually have a rise in the protein level after a period of control, and the options at that point depend on what was given before and how long the response lasted:

  • A further combination — usually making use of a class the patient has not yet had, or re-introducing one that has been off treatment for a while.
  • Bispecific antibodies directed at BCMA — antibodies that bring the patient's own T cells into contact with the plasma cell, given as a series of injections, and used for disease that has already been treated several times.
  • CAR T-cell therapy — the patient's own T cells are engineered to recognise BCMA and returned after a period of cell processing. It requires an assessment of the disease and of the patient's fitness, and the period after infusion is monitored closely.
  • A targeted drug for a defined subgroup — patients with a particular chromosome rearrangement may respond to a drug that acts on the pathway it activates, which is why the original FISH results remain relevant years later.
  • Re-treatment and trials — a treatment that worked before can work again after an interval, and clinical trials are a reasonable option at any line for patients who are eligible and willing.
  • The written history becomes the decisive information — which treatments were given, for how long, and how deep the response was. That history determines what is sensible next, and it is the part most often missing when a patient arrives having been treated elsewhere.

Supportive treatment, which is part of the plan

In myeloma the supportive measures are not adjuncts to treatment — they protect the two organs the disease damages, and they determine how much of the treatment a patient can actually receive:

  • Bone-strengthening drugs — given to reduce the risk of fractures and of further bone loss. A dental assessment is arranged before they start, because a rare complication of the jaw is much easier to prevent than to treat.
  • Calcium, vitamin D and hydration — calcium and vitamin D are corrected if low, and adequate fluid intake is encouraged because it protects the kidney.
  • Avoiding what harms the kidney — anti-inflammatory painkillers, some contrast agents and dehydration. This is one of the most concrete things a patient can act on, because these are ordinary products used for ordinary reasons.
  • Infection prevention — prophylaxis against some infections during treatment, vaccination against influenza, pneumococcal disease and shingles, and immunoglobulin replacement for patients whose antibody levels remain very low.
  • Clot prevention — the immunomodulatory drugs increase the risk of clots, so an assessment is made and a preventive measure is chosen accordingly.
  • Pain control and local treatment — analgesics taken on a schedule rather than on demand, radiotherapy to a painful deposit, and a cement injection to stabilise a collapsed vertebra where that is appropriate.
  • Physiotherapy and fall prevention — maintaining strength and balance reduces fractures, and it is more effective than asking a patient to avoid activity altogether.

How the plan is made and reviewed

Myeloma crosses several specialties because the disease affects bone, kidney, blood and in some patients the nervous system:

  • Haematology leads, choosing the combination and the sequence.
  • Radiation oncology advises when a specific deposit needs local treatment, either for pain or because it threatens a structure.
  • Orthopaedic and spinal surgery is involved when a bone needs stabilising, decompressing or supporting.
  • Nephrology advises on the kidney — which is often the organ that limits what can be given.
  • Pathology and radiology report the marrow, the chromosome findings and the imaging that the whole plan is built on.
  • Nursing and allied health deliver the prophylaxis, the apheresis and transplant care, the pain management and the physiotherapy without which the plan cannot be completed.
  • The output should be a written schedule with review points — which tests at which intervals, what result would change the treatment, and how long the current phase is expected to last. For a disease managed over years, that document is what allows care to continue coherently, including from another country.

Frequently Asked Questions

Can myeloma be treated without a transplant?

Yes, and for many patients that is the plan. Transplant is offered to patients who are fit enough for the recovery period and whose disease has responded to induction; for those who are not candidates, the standard approach is continuous combination treatment — the same drug classes, usually at a schedule designed for long-term use — given until the disease progresses. Because the combinations used in this setting are effective and much better tolerated than high-dose treatment, choosing not to transplant is a treatment decision rather than a decision to do less.

How is the response to treatment measured?

By measuring the protein the disease produces, rather than by how a patient feels. The monoclonal protein level and the free light chain ratio are rechecked at defined intervals, and the depth of their fall defines the response: a partial response means a substantial fall, a very good partial response means the protein is barely detectable, and a complete response means the standard tests can no longer find it. When the protein disappears from the blood and urine, testing the marrow with a sensitive method for residual plasma cells gives a fuller answer. This is why the exact values, with units, should be recorded at every assessment.

What happens if the kidney is already affected at diagnosis?

It changes the treatment in a defined way rather than making treatment impossible. The kidney injury is caused largely by light chains, so reducing the production of the protein is itself the treatment for the kidney, alongside correcting calcium and dehydration. Drugs that are cleared by the kidney are used with dose adjustment or avoided, one proteasome inhibitor is favoured because it can be given at full dose when the kidney is impaired, and a small number of patients need dialysis temporarily. Because the injury is often reversible, the speed of starting treatment matters — and this is a situation where delay for further investigation has a cost.

Does treatment have to continue for the rest of my life?

For most patients treatment continues at some level for a long time, but not necessarily at the same intensity. After the initial phase and a transplant, a low-dose oral drug is usually continued while it is working; for the treatment to be reduced or paused deliberately is a decision made with the team, generally on the basis of a deep and sustained response, and it is revisited at intervals. What is not advisable is to stop treatment on the basis of how well you feel, because the protein level can rise well before symptoms return, and that is exactly the signal the monitoring tests exist to detect.

Have the treatment history and results reviewed

Send the treatment record with the drugs, dates and cycles given, the response measured after each phase with the protein and light chain values, the latest blood and kidney results, and the chromosome findings from diagnosis. Our haematology team will return a written assessment within 48 hours of the file being complete.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*